Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedullary disease

The prognosis of patients with multiple myeloma (MM) with extramedullary disease (EMD) remains poor. A high overall response rate (ORR) has been reported following anti‐B‐cell maturation antigen (BCMA) chimeric antigen receptor (CAR)‐T cell therapy in relapsed/refractory (R/R) patients with MM; howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Liu, Meijing, Yuan, Ting, Yan, Lixiang, Cui, Rui, Deng, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305928/
https://www.ncbi.nlm.nih.gov/pubmed/34942032
http://dx.doi.org/10.1002/hon.2958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305928/
https://www.ncbi.nlm.nih.gov/pubmed/34942032
http://dx.doi.org/10.1002/hon.2958

Ejemplares similares